<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921920</url>
  </required_header>
  <id_info>
    <org_study_id>D9584C00010</org_study_id>
    <nct_id>NCT01921920</nct_id>
  </id_info>
  <brief_title>Prilosec Bioequivalence Study in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Single-center, 4-way Crossover, Single Dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous Solvent Based Capsules Manufactured by AstraZeneca With Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is An Open-label, Randomized, Single-center, 4-way Crossover, Single dose Bioequivalence
      Study Comparing Omeprazole 20 and 40-mg Aqueous solvent Based Capsules Manufactured by
      AstraZeneca with Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence of omeprazole 20-mg aqueous-solvent based capsules versus omeprazole 20-mg organic solvent based capsules</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence of omeprazole 40-mg aqueous-solvent based capsules versus omeprazole 40-mg organic solvent based capsules</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence of omeprazole 20-mg aqueous-solvent based capsules versus omeprazole 20-mg organic solvent based capsules</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC (0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence of omeprazole 20-mg aqueous-solvent based capsules versus omeprazole 20-mg organic solvent based capsules</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence of omeprazole 40-mg aqueous-solvent based capsules versus omeprazole 40-mg organic solvent based capsules</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC(0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence of omeprazole 40-mg aqueous-solvent based capsules versus omeprazole 40-mg organic solvent based capsules</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC(0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC(0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose.</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Bioequivalence, AUC, Cmax, Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Omeprazole 20mg aqueous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole 20mg organic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole 40mg aqueous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole 40mg organic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)</description>
    <arm_group_label>Omeprazole 20mg aqueous</arm_group_label>
    <arm_group_label>Omeprazole 20mg organic</arm_group_label>
    <arm_group_label>Omeprazole 40mg aqueous</arm_group_label>
    <arm_group_label>Omeprazole 40mg organic</arm_group_label>
    <other_name>Prilosec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers aged 18 to 50 years, inclusive, with suitable veins
             for cannulation or repeated venepuncture.

          -  Female could be of nonchildbearing potential (postmenopausal or irreversible surgical
             sterilization) and childbearing potential (negative pregnancy test at screening and
             use 2 effective methods of avoiding pregnancy).

          -  Have a body mass index (BMI) between 18 and 30 kg/m2, inclusive, and a weight of at
             least 50 kg and no more than 100 kg, inclusive.

        Exclusion Criteria:

          -  History of any clinically important disease or disorder which, in the opinion of the
             Investigator, may either put the volunteer at risk because of participation in the
             study.

          -  History or presence of gastrointestinal, hepatic, or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs.

          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks
             of the first administration of investigational medicinal product (IMP).

          -  Any clinically significant abnormalities in the physical examination, clinical
             laboratory values, 12-lead ECG, or vital signs, as judged by the Investigator.

          -  Moderate to heavy smokers (more than 10 cigarettes per day or equivalent in
             tobacco-containing products).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase I unit, Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Lunde, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omeprazole, Prilosec, Phase I, Healthy Subjects, Pharmacokinetics, Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

